From: Infliximab in the treatment of refractory uveitis. Does dose really matter?
LD | MD | HD | |
---|---|---|---|
Anatomic classification of Uveitis among cohort (%) | |||
Anterior Uveitis | 100 | 31 | 33 |
Intermediate Uveitis | 0 | <1 | 1 |
Posterior Uveitis | 0 | 26 | 33 |
Panuveitis | 0 | 42 | 44 |
Mean age at diagnosis of uveitis (yrs) | 8.9 | 8.4 | 8.5 |
Mean age of onset of treatment (yrs) | 10.8 | 10.9 | 12.1 |
Mean duration of other medication regimens prior to infliximab (yrs) | 2.0 | 2.6 | 3.5 |
Duration of treatment with topical steroids prior to infliximab (mo) | 10.6 | 12.3 | 15.4 |
Time to discontinuation of steroids after infliximab (mo) | 3.1 | 9.5 | 10.2 |
Patients requiring dose escalation (%) | 67 | 35 | 55 |
Average time to dose escalation (mo) | 5.1 | 7.5 | 14 |